{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:25:51Z","timestamp":1791919551685,"version":"4.3.4"},"reference-count":46,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/13543776.2025.2558899","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:27:12Z","timestamp":1757237232000},"page":"1141-1154","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Topoisomerase II inhibitors in oncology: an updated patent review (2016-present)"],"prefix":"10.1080","volume":"35","author":[{"given":"Eleonora","family":"Turrini","sequence":"first","affiliation":[{"name":"Alma Mater Studiorum, Universit\u00e0 di Bologna","place":["Rimini, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Maffei","sequence":"additional","affiliation":[{"name":"Alma Mater Studiorum, Universit\u00e0 di Bologna","place":["Rimini, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Milelli","sequence":"additional","affiliation":[{"name":"Alma Mater Studiorum, Universit\u00e0 di Bologna","place":["Rimini, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Fimognari","sequence":"additional","affiliation":[{"name":"Alma Mater Studiorum, Universit\u00e0 di Bologna","place":["Rimini, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101456"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm831"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032532"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2608"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010094"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929866523666160720095940"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.790958"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1879051"},{"key":"e_1_3_6_11_1","unstructured":"Worthalter AM Feldstein E Gonzalez-Buendia E. Univ Columbia. Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer. 2018:WO18094325."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00459"},{"key":"e_1_3_6_13_1","unstructured":"Kerns RJ Towle T Hiasa H. Univ Minnesota Univ Iowa res found. Quinolone-based compd anticancer activity. 2018:WO18107112."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0666-x"},{"key":"e_1_3_6_15_1","unstructured":"De Vivo M Ortega MJA Arencibia JJM et al. Univ Bologna Univ Padova Fondazione Istituto Italiano di Tecnologia. 4-amino-2-pyrido-bicyclic pyrimidines and use thereof as topoisomerase II inhibitors. 2018:WO18114700."},{"key":"e_1_3_6_16_1","unstructured":"Lu MC Sung PJ Su JH et al. Univ National Dong Hwa. Scalarane sesterterpenoid pharmaceutical composition and topoisomerase II and Hsp90 inhibitor for treating cancer and use and preparation method thereof. 2019:US10314847 BB."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep36170"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8443"},{"key":"e_1_3_6_19_1","volume-title":"Univ King Saud. Substituted naphthyridinyl hydrazines as anti-liver cancer agents","author":"Khalifa NMH","year":"2018","unstructured":"Khalifa NMH, Al-Omar MA, Amr A-G. Univ King Saud. Substituted naphthyridinyl hydrazines as anti-liver cancer agents. 2018 US9855255 BA."},{"key":"e_1_3_6_20_1","unstructured":"Huang S Huang Z Gu L et al. Univ Sun Yat Sen. Perimidine quinone derivatives and preparation method and applications thereof. 2018: CN108947916 B."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103131"},{"key":"e_1_3_6_22_1","unstructured":"Hergenrother PJ Riley AP. Univ Illinois. Topoisomerase inhibitors with antibacterial and anticancer activity. 2018:WO18237140."},{"key":"e_1_3_6_23_1","unstructured":"Du Z Li P Jiang H et al. Univ Guangdong Technology. Carbazole derivative and preparation method and application thereof in antitumor. 2018: CN107698579 B."},{"key":"e_1_3_6_24_1","unstructured":"Torro A Franc C. Novagray. A topoisomerase inhibitor for mimicking the effect of ionizing radiations on T cells. 2019:WO19234227."},{"key":"e_1_3_6_25_1","unstructured":"Tcherkassov A Alperstein Z Dong X et al. Univ British Columbia. Topoisomerase II catalytic inhibitor compound therapeutics for cancer treatment methods and uses. 2020:WO20077437."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.633142"},{"key":"e_1_3_6_27_1","unstructured":"Labarbera D Zhou Q Abraham A. Univ Colorado regents. Topoisomerase II-alpha inhibitors and methods of treating cancer using the same. 2020:WO20205991."},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.08.003"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01065"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1417201"},{"key":"e_1_3_6_31_1","unstructured":"Hou L Zhang Z Tian C et al. Univ Zhengzhou. Preparation method of lipid membrane wrapped amorphous-mesoporous manganese phosphate pharmaceutical composition with loaded DNA (deoxyribonucleic acid) topoisomerase II inhibitors. 2019 CN110123760 B."},{"key":"e_1_3_6_32_1","unstructured":"Lee ES Kwon Y Jeong TC et al. Industry academic cooperation foundation of Yeungnam Univ. Novel topoisomerase inhibitor and medical use thereof. 2021:KR102371673 B1."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2020.231"},{"key":"e_1_3_6_34_1","doi-asserted-by":"crossref","unstructured":"Perdih A Bergant K Brvar M et al. Kemijski Inst. Substituted 4 5\u2019-bithiazoles as inhibitors of the human DNA topoisomerase II. 2021:EP3811940 B1.","DOI":"10.1021\/acs.jcim.0c00202"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203283"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5RA25705K"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.09.004"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00202"},{"key":"e_1_3_6_39_1","unstructured":"Ruan J Xu M. Nanjing Hongwei Pharmaceutical Tech Co Ltd. Diterpene compound and preparation method thereof and application in preparation of antitumor drugs. 2021 CN112225656 B."},{"key":"e_1_3_6_40_1","unstructured":"Kapro\u0144 B Plech T Kocki J et al. 4-(4-phenylazophenyl)-1-(2-nitrobenzyl)-thiosemicarbazide its preparation method and its first medical use. 2023:L243704 B1."},{"key":"e_1_3_6_41_1","unstructured":"Kapro\u0144 B Plech T Kocki J et al. Univ Medyczny W Lublinie. 4-(4-phenylazophenyl)-1-[(naphth-1-yl)methyl]thiosemicarbazide its preparation method and its first medical use. 2023:L243705 B1."},{"key":"e_1_3_6_42_1","unstructured":"Kapro\u0144 B Plech T Kocki J et al. 4-[2 6-(diisopropyl)phenyl]-1-[(naphth-1-yl)methyl]thiosemicarbazide its preparation method and its first medical use. 2023:PL243706 B1."},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00151"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2022.2140420"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1320"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.09.003"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3708"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3280262427"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2558899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T03:58:05Z","timestamp":1762142285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2558899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/13543776.2025.2558899"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2558899","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}